L-selectin (CD62L) (CD62L)

L-selectin (CD62L) is a type I transmembrane glycoprotein and cell adhesion molecule that belongs to the selectin family. It is constitutively expressed on the surface of most circulating leukocytes, including naive and central memory T cells, where it plays a pivotal role in lymphocyte homing to secondary lymphoid organs by mediating the initial rolling step on high endothelial venules (HEVs) (UniProt P14151). In the context of donor T cells, CD62L expression is a key biomarker for T cell stemness and longevity; CD62L-positive T cell subsets are preferred for CAR-T cell therapies due to their superior expansion and anti-tumor persistence (PubMed: 29305548). Conversely, CD62L-mediated homing of donor T cells to recipient lymphoid tissues is a critical step in the pathogenesis of graft-versus-host disease (GvHD) following allogeneic hematopoietic stem cell transplantation (PubMed: 11588071). Therapeutic interventions targeting CD62L include monoclonal antibodies like aselizumab and small molecule selectin inhibitors, which aim to reduce pathological inflammation and GvHD by blocking leukocyte recruitment (PubMed: 15155614). Additionally, the proteolytic shedding of CD62L by ADAM17 is a significant regulatory mechanism that influences T cell activation and migration (PubMed: 22491248).

Other names

SELLLAM-1LECAM-1LNSHRLy-22CD62L antigenLeukocyte-endothelial cell adhesion molecule 1

Inhibition of L-selectin-mediated leukocyte rolling and adhesion to the vascular endothelium, thereby preventing lymphocyte recruitment to secondary lymphoid organs and sites of inflammation.